ITMIG2021 – Program
Scientific Program
TIME (EST/EDT)
EDT = Eastern Daylight Time
FRIDAY, OCTOBER 15, 2021
08:30 – 11:30 EST/EDT
COMMITTEE AND WORKING GROUP MEETINGS
All participants and ITMIG members are welcome!
08:30 – 08:40 EST/EDT – Communication Committee, Malgorzata Szolkowska, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
08:40 – 08:50 EST/EDT – Finance Committee, Joshua Sonett, The Columbia University/New York-Presbyterian Hospital, New York City, USA
08:50 – 09:00 EST/EDT – Membership Committee, Paolo Mendogni, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
09:00 – 09:30 EST/EDT – Database Committee, Nicolas Girard, The Institut Curie, Paris, France, Usman Ahmad, Heart, Vascular and Thoracic Institute, the Cleveland Clinic, Cleveland, OH, USA
09:30 – 10:00 EST/EDT – Education Committee, Mirella Marino, IRCCS Regina Elena National Cancer Institute Rome, Italy
10:00 – 10:30 EST/EDT – Steering Committee, Nicolas Girard, The Institut Curie, Paris, France
10:30 – 11:00 EST/EDT – Thymic Carcinoma Working Group, Anja Roden, The Mayo Clinic Rochester, Rochester, MN, USA
11:00 – 11:30 EST/EDT – Mediastinal Working Group, Anja Roden, The Mayo Clinic Rochester, Rochester, MN, USA
11:30 – 11:45 EST/EDT
Break
11:45 – 12:45 EST/EDT
POSTER SESSION – Live Q&A
Posters will be available on conference platform a week before the conference
11:45-12:15 EST/EDT
Poster # 3: Circulating EBV (cEBV) and metabolic imaging monitoring during therapy for thymic lymphoepithelioma-like carcinoma (tLELC ); A case study. Haim Biran, Department of Oncology, The Chaim Sheba Medical center, Ramat Gan, Israel affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
Poster # 8: Synchronous thymic and breast malignancies: a single institutional experience. Rocco Morra, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
Poster # 10: Incidental discovery of thymic masses during Sars-Cov-2 infection. Roberto Buonaiuto, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
Poster #11: Rescue Chemotherapy in a Patient with Thymoma and Severe Symptoms of Myasthenia Gravis. A case report. Magdalena Knetki-Wróblewska, Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Poster #14: A Case of Li-Fraumeni Syndrome Associated Thymoma. Sara Kuruvilla, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
Poster #20: SARS-CoV2 infection in patient with thymoma: presentation of two cases. Mirella Marino, Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
12:15-12:45 EST/EDT
Poster #5: Post operative management and outcome of high risk thymoma and thymic carcinoma following curative intent surgery. A single centre experience. Maggie Harris, The Christie NHS Foundation Trust, Manchester, UK
Poster # 9: Pitfalls in mediastinal masses diagnosis. Aldo Caltavituro, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
Poster #17: Oncological outcomes of robotic extended thymectomy for early stage thymoma compared to sternotomy: a retrospective single centre institution analysis. Filippo Tommaso Gallina, Thoracic Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Poster #18: Advances in mediastinal tumors diagnosis: J. Rosai, a master of Pathology, and the value of morphology and related disciplines. Lucia Anemona, Department of Experimental Medicine, Faculty of Medicine, Tor Vergata University, Rome, Italy
Poster #19: Extended subxiphoid thymectomy for a large B3/B2 thymoma with positive acetylcholine receptor antibodies but without myasthenia/Video. Tibor Krajc, Department of Thoracic Surgery, Klinik Floridsdorf Vienna, Austria
Poster #21: Histopathologic characteristics of resected thymic cyst walls, with imaging correlation. Julian A. Villalba, James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
12:45 – 13:00 EST/EDT
Break
13:00 – 14:00 EST/EDT
PLENARY SESSION
Chair/Moderator:
Frank Detterbeck, The Yale University School of Medicine, New Haven, CT, USA
ITMIG Prospective Database – a worldwide project for thymic tumors
Nicolas Girard, The Institut Curie, Paris, France (15 min)
Advances in thoracic surgery for thymic tumors
Jens Ruckert, Competence Center for Thoracic Surgery, Surgical Clinic of the University Medicine Berlin (Charité), Berlin, Germany (15 min)
Advances in systemic therapy for thymic tumors
Patrick Loehrer, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, USA (15 min)
Live Q&A
TIME (EST/EDT)
EDT = Eastern Daylight Time
SATURDAY, OCTOBER 16, 2021
08:30 – 08:40 EST/EDT
Opening of a conference
08:40 – 09:50 EST/EDT
Session 1: The small mediastinal lesion and early-stage thymic tumor
Chairs/Moderators:
Paul Van Schil, The Antwerp University Hospital and Antwerp University, Department of Thoracic and Vascular Surgery, Edegem (Antwerp), Belgium
Charles Simone, The Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, USA
Imaging the small mediastinal lesion
Edith Marom, The Chaim Sheba Medical Center, Ramat Gan, Israel (15 min)
The small mediastinal lesion – management options
Joshua Sonett, The Columbia University/New York-Presbyterian Hospital, New York City, USA (15 min)
Thymomectomy or complete thymectomy of early-stage thymic tumor: Thymomectomy is sufficient
Wentao Fang, The Shanghai Chest Hospital, Shanghai, China (10 min)
Thymomectomy or complete thymectomy of early-stage thymic tumor: Complete thymectomy is more effective
Marlies Keijzers, The Maastricht University Medical Center, Maastricht, The Netherlands (10 min)
Oral Abstract Presentations
Robotic thymectomy for thymomas: a retrospective follow-up study in the Netherlands, Florit Marcuse, Department of Pulmonology, Maastricht University Medical Center+, Maastricht, the Netherlands (10 min)
Optimal delineation of the clinical target volume for thymomas in the postoperative setting: a multi-center study, Florit Marcuse, Department of Pulmonology, Maastricht University Medical Center+, Maastricht, the Netherlands (10 min)
09:50 – 10:20 EST/EDT
Live Q&A
10:20 – 10:40 EST/EDT
Break
10:40 – 12:05 EST/EDT
Session 2: Thymic tumors and clinical correlates (part 1):
Neurological comorbidities, TETs in children
Chair/Moderator: Giuseppe Cardillo, Thoracic Surgery, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
Paraneoplastic syndromes associated with thymoma beyond myasthenia gravis
Berthold Schalke, Neurologische Klinik und Poliklinik der Universität Regensburg, Regensburg, Germany (15 min)
Multidisciplinary approach to pre- and post-thymectomy care of thymoma patients
Anna Kostera-Pruszczyk, The Medical University of Warsaw, Central University Hospital, Warsaw, Poland (15 min)
Clinical and laboratory features heralding the appearance of thymomas
Mohammad Ashraghi, The Nuffield Department of Clinical Neurosciences, The John Radcliffe Hospital, Oxford, UK (15 min)
Clinical workup of the asymptomatic patient with suspected thymoma
Alper Toker, The West Virginia University Heart and Vascular Institute, Morgantown, WV, USA (15 min)
Thymic tumors in children
Daniel Orbach, The Institut Curie, SIREDO Oncology Center, Paris, France (15 min)
Oral Abstract Presentation
Subclinical myasthenia gravis in thymomas, Florit Marcuse, Department of Pulmonology, Maastricht University Medical Center+, Maastricht, the Netherlands (10 min)
12:05 – 12:35 EST/EDT
Live Q&A
12:35 – 13:05 EST/EDT
Break
13:05 – 14:30 EST/EDT
Session 3: Thymic tumors and clinical correlates (part 2):
Thymic pathology and SARS-CoV-2 infection
Chair/Moderator: Sukhmani Padda, The Cedars-Sinai Medical Center, Los Angeles, USA
Thymic pathology in COVID-19 patients
Amira Marouf, Critical Care Medicine & Clinical Research Departments, Clinique Ambroise Paré, Neuilly Sur Seine, France (15 min)
COVID-19 in patients with myasthenia gravis
Richard Nowak, The Department of Neurology, The Yale School of Medicine, New Haven, CT, USA (15 min)
Effect of SARS-CoV-2 epidemic on the management of thymic tumor patients
Alan Kirk, Golden Jubilee National Hospital, Clydebank, Scotland, United Kingdom (15 min)
Oral Abstract Presentations
Preliminary data of immunogenicity of SARS-COV-2 mRNA vaccine in Thymic Epithelial Tumors, Erica Pietroluongo, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy (10 min)
Tolerability of COVID-19 mRNA Vaccines in Patients with Thymic Epithelial Tumors, Madison Ballman, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA (10 min)
Molecular Profiling of Genetic Alterations in Thymic Epithelial Tumors by Targeted Next Generation Sequencing – A Pilot Study, Adam Szpechcinski, Department of Genetics and Clinical Immunology, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland (10 min)
Different pattern of IDO 1 and PD-L1 immunoexpression in Thymomas, Surabhi Jain, Department of Pathology, All India Institute of Medical Sciences, New Delhi, India (10 min)
14:30 – 15:00 EST/EDT
Live Q&A
TIME (EST/EDT)
EDT = Eastern Daylight Time
SUNDAY, OCTOBER 17, 2021
08:30 – 09:50 EST/EDT
Session 4: Metastatic pleural disease in the course of TETs – multidisciplinary approach
Chair/Moderator: Andreas Rimner, Memorial Sloan Kettering Cancer Center, New York, USA
Cases presentation – what strategy do you propose? (I-st voting)
Conrad Falkson, The Queen’s University and Kingston Health Sciences Center, Kingston, Ontario, Canada (15 min)
Imaging of metastatic pleural dissemination
Jeanne Ackman, Harvard Medical School, Massachusetts General Hosptial, Boston, MA, USA (15 min)
Surgical options for treatment of metastatic pleural disease
Meinoshin Okumura, The National Hospital Organization, The Osaka Toneyama Medical Center, Toyonaka, Japan (15 min)
Radiation strategy and technics for metastatic pleural disease
Annemarie Shepherd, The Memorial Sloan Kettering Cancer Center, New York City, NY, USA (15 min)
When to observe and when to start systemic therapy? Systemic treatment options for metastatic pleural disease
Gregory Riely, The Memorial Sloan Kettering Cancer Center, New York, USA (15 min)
Cases presentation – re-evaluation. What strategy do you propose now? (II-nd voting)
Conrad Falkson, The Queen’s University and Kingston Health Sciences Center, Kingston, Ontario, Canada (5 min)
09:50 – 10:20 EST/EDT
Live Q&A
10:20 – 10:50 EST/EDT
Break
10:50 – 12:10 EST/EDT
Session 5: Updates in mediastinal tumors classifications:
TNM 8th Ed.,
WHO 2021 histological classification
Mediastinal compartments/CT
Chair/Moderator: Enrico Ruffini, The University of Torino, Torino, Italy
TNM 8th. Ed. staging of TETs – UPDATE – Pathologist’s perspective
Thierry Molina, The APHP, The University of Paris, Robert Debré and Necker Enfants Malades Hospitals, Paris, France (10 min)
TNM 8th. Ed. staging of TETs – UPDATE – Surgeon’s perspective
Dong Kwan Kim, The Asan Medical Center, Seoul, KOREA (10 min)
TNM 8th. Ed. staging of TETs – UPDATE – Medical oncologist’s perspective
Nicolas Girard, The Institut Curie, Paris, France (10 min)
TNM 8th. Ed. staging of TETs – UPDATE – Radiation oncologist’s perspective
Abigail Berman, University of Pennsylvania Health System, Philadelphia, PA, USA (10 min)
WHO 2021 histological classification for mediastinal tumors
Alexander Marx, The Institute of Pathology, The University Medical Centre Mannheim, The University of Heidelberg, Mannheim, Germany (10 min)
ITMIG classification (CT-based) of mediastinal compartments
Brett Carter, MD Anderson Cancer Center, Houston, Texas, USA (10 min)
Oral Abstract Presentations
Importance of an international refining of histopathological criteria of pT in Thymic Epithelial Tumors: a RYTHMIC/ITMIG study, Thierry Molina, Pathology, University of Paris, Necker Enfants Malades and Robert Debre Hospitals, APHP, Paris (10 min)
Transcriptional and chromatin profiling reveals the molecular architecture and druggable vulnerabilities of TETs, Pierluigi Manti, Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy (10 min)
12:10 – 12:40 EST/EDT
Live Q&A
12:40 – 13:10 EST/EDT
Break
13:10 – 13:50 EST/EDT
Session 6: Thymic carcinomas vs. lung carcinomas
Chair/Moderator: James Huang, The Memorial Sloan Kettering Cancer Center, New York, USA
Thymic carcinomas vs. lung carcinomas – Radiologist’s perspective
Chad Strange, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA (10 min)
Thymic carcinomas vs. lung carcinomas – Pathologist’s perspective
Malgorzata Szolkowska, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland (10 min)
Thymic carcinomas vs. lung carcinomas – Surgeon’s perspective
Frank Detterbeck, The Yale University School of Medicine, New Haven, CT, USA (10 min)
Thymic carcinomas vs. lung carcinomas – Medical oncologist’s perspective
Arun Rajan, The National Cancer Institute, The National Institutes of Health (NCI/NIH), Bethesda, USA (10 min)
13:50 – 14:10 EST/EDT
Live Q&A
14:10 – 14:50 EST/EDT
Live Tumor Board: presentation of a case of advance thymic epithelial tumor
Presenter: Marcin Zielinski, The Pulmonary Hospital “Odrodzenie” of the name of Klara Jelska, Zakopane, Poland (10 min)
Experts panel:
Anja Roden, The Mayo Clinic Rochester, Rochester, MN, USA
Mylene Truong
Dirk Van Raemdonck, University Hospital Gasthuisberg, Leuven, Belgium
Ritsuko Komaki, Baylor College of Medicine in Houston TX, USA
Heather Wakelee, Stanford University, Stanford, CA, USA
14:50 – 15:00 EST/EDT